VYNE Therapeutics Inc.
VYNE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 144.9% | -65.8% | 140.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -4,390.5% | -10,921.7% | -4,550% | -15,202.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -4,307.7% | -8,340.6% | -4,262.9% | -14,311.9% |
| EPS Diluted | -0.17 | -0.13 | -0.2 | -0.28 |
| % Growth | -30.8% | 35% | 28.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |